Skip to Main Content

An Open-Label, Dose-Escalation Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-573 in Adult Patients With Metastatic Solid Tumors

Conditions

Phase I

Phase I

What is the purpose of this trial?

The purpose of this study is to determine the safety and tolerability of TAK-573 in participants with locally advanced or metastatic solid tumors.

  • Trial with
    Millennium Pharmaceuticals, Inc.
  • Start Date
    11/19/2020
  • End Date
    08/02/2023

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/15/2021
  • Study HIC
    #2000027295